DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand.
$2.38-12.84%
报价 2026-11-06
市值
$23.3M
EV
$62.7M
PE (TTM)
5.5x
预期 PE (FY2026)
–
52 周区间距高点 -83.0%
$2.38$14.00
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| DRIODarioHealth Corp. | $23.3M | -12.8% | +17.4% | 56.1% | 5.5x | – | – | |
| ABSIAbsci Corporation | $1.75B | +8.3% | +2.8% | -255.9% | – | – | – | |
| INNVInnovAge Holding Corp. | $1.22B | -1.3% | +11.4% | 17.7% | 165.1x | 30.4x | 17.5x | |
| VSTMVerastem, Inc. | $1.02B | -10.3% | +251.3% | 86.7% | – | – | – | |
| PACBPacific Biosciences of California, Inc. | $700.9M | -7.2% | +6.3% | 36% | – | – | – | |
| FLGTFulgent Genetics, Inc. | $653.2M | +27.2% | +8.5% | 33.8% | – | – | – | |
| MYGNMyriad Genetics, Inc. | $566.2M | -5.9% | +5.1% | 68.8% | – | – | – | |
| RGNXREGENXBIO Inc. | $503M | +3.3% | +36.7% | 54.2% | – | – | – | |
| OFIXOrthofix Medical Inc. | $318.1M | -11.8% | +4.9% | 69.6% | – | 5.7x | – | |
| 同行中位数 | – | – | +7.4% | 45.1% | 165.1x | 18.0x | 17.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。